Paul Fatheree is senior vice president of medicinal chemistry at DICE Therapeutics. He has more than 25 years of medicinal chemistry experience in roles of increasing leadership and has successfully overseen the chemistry and early CMC activities for multiple research programs. Most recently, Paul was vice president of chemistry at ViewPoint Therapeutics, where he oversaw the discovery and early development of small molecule correctors of misfolded proteins. Prior to ViewPoint, he was senior director of chemistry at Theravance Biopharma, where he was involved in the identification of over 7 differentiated clinical candidates across multiple indications, target classes, and routes of administration including Vibativ®, Velusetrag, Cefilavancin and TD-8236, a novel, inhaled pan-JAK inhibitor. Prior to Theravance BioPharma, Paul was a chemist at Arris Pharmaceuticals and Syntex Research.
Paul holds a B.S. in chemistry from the University of California, Santa Barbara.